Revolution Medicines Officer Sells Shares for Tax Withholding Under Rule 10b5-1
Revolution Medicines, Inc.
Subscribe to track RVMD
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Insider Sale Alert: Revolution Medicines, Inc. (RVMD)
**Insider:** Stephen Michael Kelsey
**Title:** Senior Advisor to the Chief Executive Officer
**Filing Date:** 2026-09-18 | **Transaction Date:** 2026-09-16
### Transaction Summary
* **Type:** Open Market Sale (Rule 10b5-1 / Tax Withholding)
* **Shares Sold:** 5,569
* **Average Price:** ~$199.24
* **Total Proceeds:** ~$1,109,553.58
* **Remaining Ownership:** 286,307 shares (Direct)
### Significance
* **Rating:** Low
* **Notes:** Mandated sales executed under a Rule 10b5-1 instruction plan adopted on May 31, 2023, specifically to satisfy tax withholding obligations triggered by RSU vesting.
Comprehensive Analysis
Executive Summary
On September 18, 2026, Revolution Medicines, Inc. ($RVMD) filed Form 4 disclosing open market dispositions of common stock by Stephen Michael Kelsey, Senior Advisor to the Chief Executive Officer. Kelsey disposed of a total of 5,569 shares on September 16, 2026, for total gross proceeds of approximately $1.11 million.
Transaction Details
The transactions took place across two tranches:
- 85 shares sold at a weighted average price of $195.0074 (ranging from $195.00 to $195.03), generating $16,575.63.
- 5,484 shares sold at a price of $199.3032, generating $1,092,978.75.
Combined, the weighted average execution price was approximately $199.24 per share.
Trading Context & Market Impact
- Rule 10b5-1 & Tax Withholding: Footnote 1 confirms the dispositions were carried out pursuant to a Rule 10b5-1 plan established on May 31, 2023, designated specifically to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- Net Exposure: Following the transaction, Kelsey retains direct beneficial ownership of 286,307 shares, which includes 65,613 RSUs. The shares sold represent roughly 1.91% of his total pre-transaction holdings.
- Significance Evaluation: Assessed as Low Significance. The transaction was non-discretionary, scheduled under a pre-established 10b5-1 instruction letter, and driven by statutory tax withholding obligations rather than negative sentiment regarding the issuer's pipeline or operational prospects.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.